Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919328 | 0.89 | TBK1 (0.85) | IKBKETBK1 | |
| SCHEMBL20918384 | 0.88 | TBK1 (0.68) | IKBKETBK1 | |
| SCHEMBL20934755 | 0.88 | IKBKE (0.60) | IKBKETBK1 | |
| SCHEMBL15939760 | 0.84 | IKBKE (1.00) | IKBKETBK1 | |
| SCHEMBL20919354 | 0.83 | TBK1 (0.86) | IKBKETBK1 | |
| SCHEMBL20935050 | 0.83 | TBK1 (0.68) | IKBKETBK1 | |
| SCHEMBL20934808 | 0.82 | IKBKE (0.72) | IKBKETBK1 | |
| SCHEMBL20934797 | 0.82 | TBK1 (0.67) | IKBKETBK1 | |
| SCHEMBL20919388 | 0.81 | TBK1 (1.00) | IKBKETBK1 | |
| SCHEMBL24904122 | 0.81 | TBK1 (0.62) | IKBKETBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | IKBKE 5/4885TBK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.